AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20409019 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-quarter circumferential band configuration (PB)
Number of subjects: 47
Study 20409019 — intervention group
Group type: COMPARATOR
Intervention: Full circumferential band configuration (FB)
Number of subjects: 47
Study 17360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 57
Study 17360125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16275869 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF at 10 microg/kg body weight for 6 days in addition to standard care (aspirin, clopidogrel, ACE inhibitor, beta-blocking agents, statins)
Number of subjects: 50
Study 16275869 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 50
Study 11929645 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol/150 microg levonorgestrel (three cycles)
Number of subjects: 12
Study 11929645 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol/75 microg gestodene (three cycles)
Number of subjects: 12
Study 11929645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contraceptive treatments
Number of subjects: 12
Study 9852409 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis RBCs
Number of subjects: 21
Study 9852409 — intervention group
Group type: COMPARATOR
Intervention: Manual RBCs
Number of subjects: 21
Study 8572909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger condition
Number of subjects: 48
Study 8572909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety condition
Number of subjects: 48
Study 8572909 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 48
Study 2242519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 183
Study 2242519 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 183
Study 28313 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg (Halcion)
Number of subjects: 239
Study 28313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 31429793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NFX/120HD)
Number of subjects: 0
Study 31429793 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN/60CD)
Number of subjects: 0
Study 31429793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28075066 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin + Metformin FDC (12.5 mg + 500 mg BID)
Number of subjects: 647
Study 28075066 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 mg BID)
Number of subjects: 647
Study 28075066 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BID)
Number of subjects: 647
Study 28075066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study 26175027 — intervention group
Group type: EXPERIMENTAL
Intervention: TDEN vaccine (two formulations)
Number of subjects: 636
Study 26175027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study 23222078 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 20)
Number of subjects: 39
Study 23222078 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 39
Study 21746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to secondhand smoke exposure (SHSe)
Number of subjects: 0
Study 21746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SHSe reactions
Number of subjects: 0
Study 21746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of smoking susceptibility
Number of subjects: 0
Study 19840752 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative pedography (IP) used in 52 patients.
Number of subjects: 100
Study 19840752 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative pedography (control group).
Number of subjects: 100
Study 16424233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid IL-6 concentrations at presentation
Number of subjects: 0
Study 16424233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid inflammatory cytokines
Number of subjects: 0
Study 16424233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid IFN-gamma concentrations
Number of subjects: 0
Study 16424233 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood IFN-gamma ELISPOT responses to Mycobacterium tuberculosis Ags (ESAT-6, CFP-10, PPD)
Number of subjects: 0
Study 16424233 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid inflammatory indices
Number of subjects: 0
Study 14871958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with HLA‐A2‐restricted hTERT I540 peptide presented with keyhole limpet hemocyanin by ex vivo generated autologous dendritic cells
Number of subjects: 7
Study 14871958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with hTERT peptide
Number of subjects: 7
Study 11407800 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm artificial limb-length discrepancy
Number of subjects: 44
Study 11407800 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm artificial limb-length discrepancy
Number of subjects: 44
Study 11407800 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm artificial limb-length discrepancy
Number of subjects: 44
Study 11407800 — intervention group
Group type: COMPARATOR
Intervention: 0 cm artificial limb-length discrepancy (control)
Number of subjects: 44
Study 11185668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (single oral doses ranging from 2.5 to 20 mg)
Number of subjects: 42
Study 11185668 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy volunteers)
Number of subjects: 42
Study 8965040 — intervention group
Group type: EXPERIMENTAL
Intervention: Echotrace (graphic software system)
Number of subjects: 29
Study 1495686 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary closure
Number of subjects: 33
Study 1495686 — intervention group
Group type: COMPARATOR
Intervention: Secondary intention
Number of subjects: 33
Study 6188892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol (150 mg/30 min)
Number of subjects: 12
Study 6188892 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (250 mg/30 min)
Number of subjects: 12
Study 29251176 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion (egocentric perspective)
Number of subjects: 6
Study 29251176 — intervention group
Group type: EXPERIMENTAL
Intervention: Distancing (observer perspective)
Number of subjects: 6
Study 29251176 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by Beck Depression Inventory-II
Number of subjects: 6
Study 29251176 — intervention group
Group type: COMPARATOR
Intervention: Distancing
Number of subjects: 6
Study 29322594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 30
Study 26956726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions including outreach visits, a website with recommendations, tools for managing depression, and a continuous medical education course for general practitioners.
Number of subjects: 900
Study 26956726 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without tailored interventions).
Number of subjects: 900
Study 25377015 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC) management
Number of subjects: 146
Study 25377015 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 146
Study 22727733 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400mg orally b.i.d. on a continuous basis
Number of subjects: 602
Study 22727733 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study 20797314 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 gene polymorphisms (CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, CYP1A2*1F)
Number of subjects: 100
Study 20797314 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 100
Study 18240834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient vigilance system (passive sensor array and bedside unit connected to nurse call system)
Number of subjects: 0
Study 18240834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient vigilance system
Number of subjects: 0
Study 15856079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or bupropion treatment for 5 weeks
Number of subjects: 13
Study 11991878 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled substance P
Number of subjects: 12
Study 11991878 — intervention group
Group type: COMPARATOR
Intervention: Inhaled neurokinin A (Control)
Number of subjects: 12
Study 9805723 — intervention group
Group type: EXPERIMENTAL
Intervention: New antenatal care programme
Number of subjects: 24000
Study 9805723 — intervention group
Group type: COMPARATOR
Intervention: Traditional programme currently in use
Number of subjects: 24000
Study 7701550 — intervention group
Group type: COMPARATOR
Intervention: Immuninehep-plus
Number of subjects: 53
Study 7701550 — intervention group
Group type: COMPARATOR
Intervention: Immuninehep-minus
Number of subjects: 53
Study 7701550 — intervention group
Group type: COMPARATOR
Intervention: Bebulin (control)
Number of subjects: 53
Study 2482677 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 6% (mean molecular weight = 40,000)
Number of subjects: 10
Study 2482677 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 10
Study 30051418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 36
Study 30051418 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 28602783 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended pharmacotherapy
Number of subjects: 790
Study 28602783 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis knowledge
Number of subjects: 790
Study 28602783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of adverse effects
Number of subjects: 790
Study 28602783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dislike of taking medicine
Number of subjects: 790
Study 28602783 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that medication would not help
Number of subjects: 790
Study 25091720 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based relapse prevention program (CBRP)
Number of subjects: 71
Study 22651242 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by nurse specialists
Number of subjects: 0
Study 22651242 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual by GPs (Control)
Number of subjects: 0
Study 22651242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialist involvement (from GPs' perspective)
Number of subjects: 0
Study 21692759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sled-mounted needle guide (sled group, n = 23)
Number of subjects: 50
Study 21692759 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound without the sled (control group, n = 27)
Number of subjects: 50
Study 21692759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sled group
Number of subjects: 50
Study 21692759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 19635615 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA (20 mg)/CE (0.625 or 0.45 mg)
Number of subjects: 3397
Study 19635615 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA/CE
Number of subjects: 3397
Study 19635615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 16456441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy before day 8 postinjury
Number of subjects: 60
Study 16456441 — intervention group
Group type: COMPARATOR
Intervention: Tracheostomy after day 28 postinjury
Number of subjects: 60
Study 15242359 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (50-75 mg daily)
Number of subjects: 49
Study 15242359 — intervention group
Group type: COMPARATOR
Intervention: Eviprostat (six tablets daily)
Number of subjects: 49
Study 11760371 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks (regimen A)
Number of subjects: 36
Study 11760371 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks followed by interferon alfa 3 MU thrice weekly for another 24 weeks (regimen B)
Number of subjects: 36
Study 9531230 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens 0.3 mg/d
Number of subjects: 406
Study 9531230 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens 0.625 mg/d
Number of subjects: 406
Study 9531230 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens 1.25 mg/d
Number of subjects: 406
Study 9531230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 8237801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 159
Study 8237801 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 159
Study 3307421 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium
Number of subjects: 18
Study 3307421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30324560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable toothbrush (CT)
Number of subjects: 60
Study 30324560 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MT)
Number of subjects: 60
Study 28600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 5 hours after insemination
Number of subjects: 85
Study 28600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 6 hours after insemination
Number of subjects: 85
Study 28600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 4 hours after insemination
Number of subjects: 85
Study 28600104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue intracytoplasmic sperm injection (ICSI)
Number of subjects: 85
Study 28600104 — intervention group
Group type: COMPARATOR
Intervention: Spindle visualization method
Number of subjects: 85
Study 26196502 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 12 weeks
Number of subjects: 203
Study 26196502 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 8 weeks
Number of subjects: 203
Study 26196502 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus Sofosbuvir across all genotypes
Number of subjects: 203
Study 23521151 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based nomogram alone (Group 1)
Number of subjects: 57
Study 23521151 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based nomogram combined with suprasternal palpation (Group 2)
Number of subjects: 57
Study 23521151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of weight-based and suprasternal methods by personnel not specially trained (Group 3)
Number of subjects: 57
Study 21417936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (group A)
Number of subjects: 125
Study 21417936 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine (group B)
Number of subjects: 125
Study 21417936 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment stent placement
Number of subjects: 125
Study 19105585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg, twice daily for 24 weeks
Number of subjects: 2088
Study 19105585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2088
Study 16612142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic gels containing ibuprofen
Number of subjects: 0
Study 16612142 — intervention group
Group type: COMPARATOR
Intervention: 36.5‐mM concentration of methyl nicotinate
Number of subjects: 0
Study 16612142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lamivudine (100 mg daily) and IFN‐alpha‐2b (10 million U 3 times per week for 12 months)
Number of subjects: 49
Study 12802750 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha‐2b monotherapy (10 million U 3 times per week for 12 months)
Number of subjects: 49
Study 12802750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 49
Study 10793324 — intervention group
Group type: EXPERIMENTAL
Intervention: Opipramol (200 mg/day)
Number of subjects: 200
Study 10793324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8871411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismissing adult attachment group
Number of subjects: 0
Study 8871411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoccupied adult attachment group
Number of subjects: 0
Study 8871411 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous adult attachment group
Number of subjects: 0
Study 1386490 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg daily)
Number of subjects: 40
Study 1386490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 to 80 mg daily in slow-release form)
Number of subjects: 40
Study 1386490 — intervention group
Group type: COMPARATOR
Intervention: Both perindopril and nifedipine
Number of subjects: 40
Study 1386490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40
Study 6526628 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer technique
Number of subjects: 172
Study 6526628 — intervention group
Group type: COMPARATOR
Intervention: Double layer technique
Number of subjects: 172
Study 30463577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine
Number of subjects: 60
Study 30463577 — intervention group
Group type: COMPARATOR
Intervention: Syringe lidocaine
Number of subjects: 60
Study 24632753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg twice a day plus nucleoside reverse transcriptase inhibitors
Number of subjects: 56
Study 23394476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (Merci Retriever or Penumbra System)
Number of subjects: 118
Study 23394476 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 23394476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (favorable penumbral pattern)
Number of subjects: 118
Study 23394476 — intervention group
Group type: COMPARATOR
Intervention: Standard care (favorable penumbral pattern)
Number of subjects: 118
Study 23394476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (nonpenumbral pattern)
Number of subjects: 118
Study 23394476 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nonpenumbral pattern)
Number of subjects: 118
Study 20719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI (obese III)
Number of subjects: 36941
Study 20719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline height
Number of subjects: 36941
Study 20719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline weight, waist circumference, hip circumference, waist-to-hip ratio (WHR)
Number of subjects: 36941
Study 18458278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 18458278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 17129904 — intervention group
Group type: EXPERIMENTAL
Intervention: Project LIGHT (seven-session, small-group intervention)
Number of subjects: 99
Study 17129904 — intervention group
Group type: COMPARATOR
Intervention: One-session video intervention
Number of subjects: 99
Study 12614248 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin-GITS
Number of subjects: 52
Study 12614248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 52
Study 11155006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (weight-adapted dosing based on body weight)
Number of subjects: 1190
Study 11155006 — intervention group
Group type: COMPARATOR
Intervention: Heparin sodium (fixed dose of 3,000 IU)
Number of subjects: 1190
Study 8957719 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin monotherapy
Number of subjects: 55
Study 1552197 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside therapy
Number of subjects: 184
Study 1552197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 184
Study 3549878 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 51
Study 3549878 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 51
Study 31436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat application
Number of subjects: 62
Study 31436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 62
Study 31436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after heat application
Number of subjects: 62
Study 31436359 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 62
Study 29465560 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 124
Study 29465560 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 124
Study 26746195 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 50
Study 26746195 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 50
Study 26746195 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 50
Study 24837863 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) exposure before very preterm birth
Number of subjects: 0
Study 22717418 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO‐A 1 × 5 mg
Number of subjects: 35
Study 22717418 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 5 mg
Number of subjects: 35
Study 22717418 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO‐A 2 × 7.5 mg (fasted)
Number of subjects: 35